SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Open

BrancheGesundheitswesen

115.7 1.76

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

113.8

Max

115.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

215M

Verkäufe

785M

KGV

Branchendurchschnitt

31.236

57.333

Dividendenrendite

0.79

Gewinnspanne

11.32

Angestellte

14,147

EBITDA

161M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+16.61% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.79%

2.63%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-117M

13B

Vorheriger Eröffnungskurs

113.94

Vorheriger Schlusskurs

115.7

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

BioMerieux Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Apr. 2025, 08:49 UTC

Wichtige Markttreiber

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Peer-Vergleich

Kursveränderung

BioMerieux Prognose

Kursziel

By TipRanks

16.61% Vorteil

12-Monats-Prognose

Durchschnitt 133.17 EUR  16.61%

Hoch 140 EUR

Tief 127 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioMerieux – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

113.8 / 118.9Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.